Open access
Jul 2026
Engineered PD1-NKG2D Dual-CAR NK92 cells broaden antitumor target recognition in preclinical tumor models
Dual-target PD1/NKG2D CAR-NK92 cells exhibit broadened antitumor activity across tumor cells with distinct ligand-expression profiles and may represent a promising strategy to reduce the limitations associated with single-target CAR therapies.
Xinru Jin, Mingfeng Li, Mengjun Wang et al.
· Journal of Translational Med... · 0 citations